Santhera Pharmaceuticals Holding (SPHDF) Price & Analysis

Compare

38 Followers

SPHDF Stock Chart & Stats

$13.25

$0.00(0.00%)

At close: Dec 03 4:00 PM EST

$13.25

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$9.42 - $19.65

Previous CloseN/A

Volume890.00

Average Volume (3M)37.00

Market Cap

$219.24M

Enterprise Value$210.76M

Total Cash (Recent Filing)$18.40M

Total Debt (Recent Filing)$76.30M

Price to Earnings (P/E)―

Beta-0.54

Next Earnings

Apr 23, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.81

Shares Outstanding14,012,004

10 Day Avg. Volume40

30 Day Avg. Volume37

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)5.68

Price to Sales (P/S)4.02

P/FCF Ratio-4.41

Enterprise Value/Market Cap0.96

Enterprise Value/Revenue4.30

Enterprise Value/Gross Profit35.80

Enterprise Value/Ebitda-6.48

Forecast

1Y Price Target

$37.96

Price Target Upside186.49% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial PerformanceSanthera's expectation for FY2025 top-line revenue to exceed the previously stipulated guidance range indicates positive financial growth.

Market ExpansionAn exclusive distribution agreement for vamorolone has been established in Russia, allowing access to AGAMREE for Duchenne muscular dystrophy patients across the country.

Product EfficacySanthera's AGAMREE (vamorolone) demonstrates durable efficacy with maintained motor function over extended follow-up, comparable to standard-of-care corticosteroids.

Bears Say

Santhera Pharmaceuticals Holding News

Santhera Pharmaceuticals Advances Vamorolone Study for Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding Ag (($SPHDF)) announced an update on their ongoing clinical study. Santhera Pharmaceuticals is conducting a...

2M ago

SPHDF

Santhera’s Earnings Call: Positive Outlook Amid Challenges

Santhera Pharmaceuticals Holding Ag (($CH:SANN)) has held its Q2 earnings call. Read on for the main highlights of...

3M ago

Santhera Pharmaceuticals Reports Strong H1 2025 Growth

Santhera Pharmaceuticals Holding Ag ( ($SPHDF) ) has released its Q2 earnings. Here is a breakdown of the...

3M ago

Santhera price target raised to CHF 30 from CHF 25 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Santhera Pharmaceuticals (SPHDF) to CHF 30 from CHF 25 and...

7M ago

Santhera Pharmaceuticals: Buy Rating Affirmed on Strong Commercial Traction and Promising Financial Outlook

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Santhera Pharmaceuticals Holding (SPHDF – Research Report) today...

7M ago

Santhera Pharmaceuticals: Transformative Year with AGAMREE Success

Santhera Pharmaceuticals Holding Ag ( ($SPHDF) ) has released its Q4 earnings. Here is a breakdown of the...

8M ago

Santhera Pharmaceuticals: Buy Rating Affirmed on Strategic Milestones and Growth Prospects

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Santhera Pharmaceuticals Holding...

10M ago

Santhera price target lowered to CHF 25 from CHF 30 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Santhera Pharmaceuticals to CHF 25 from CHF 30 and keeps...

1y ago

SPHDF FAQ

What was Santhera Pharmaceuticals Holding’s price range in the past 12 months?

Santhera Pharmaceuticals Holding lowest stock price was $9.42 and its highest was $19.65 in the past 12 months.

What is Santhera Pharmaceuticals Holding’s market cap?

Santhera Pharmaceuticals Holding’s market cap is $219.24M.

When is Santhera Pharmaceuticals Holding’s upcoming earnings report date?

Santhera Pharmaceuticals Holding’s upcoming earnings report date is Apr 23, 2026 which is in 119 days.

How were Santhera Pharmaceuticals Holding’s earnings last quarter?

Santhera Pharmaceuticals Holding released its earnings results on Sep 23, 2025. The company reported -$3.806 earnings per share for the quarter, missing the consensus estimate of -$0.751 by -$3.054.

Is Santhera Pharmaceuticals Holding overvalued?

According to Wall Street analysts Santhera Pharmaceuticals Holding’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Santhera Pharmaceuticals Holding pay dividends?

Santhera Pharmaceuticals Holding does not currently pay dividends.

What is Santhera Pharmaceuticals Holding’s EPS estimate?

Santhera Pharmaceuticals Holding’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Santhera Pharmaceuticals Holding have?

Santhera Pharmaceuticals Holding has 14,012,004 shares outstanding.

What happened to Santhera Pharmaceuticals Holding’s price movement after its last earnings report?

Santhera Pharmaceuticals Holding reported an EPS of -$3.806 in its last earnings report, missing expectations of -$0.751. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Santhera Pharmaceuticals Holding?

Currently, no hedge funds are holding shares in SPHDF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Santhera Pharmaceuticals Holding

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.

Santhera Pharmaceuticals Holding (SPHDF) Earnings & Revenues

Historic Earnings Reports

SPHDF Company Deck

SPHDF Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented a positive outlook with significant market adoption of AGAMREE in Europe and the U.S., strong commercial rollout in China, and increased revenue guidance. However, challenges such as a considerable operating loss and the need for additional financing were also highlighted.View all SPHDF earnings summaries

SPHDF Stock 12 Month Forecast

Average Price Target

$37.96

▲(186.49% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","23":"$23","38":"$38","15.5":"$15.5","30.5":"$30.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":37.96242,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$37.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37.96,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$37.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37.96242,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$37.96</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,15.5,23,30.5,38],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.8,14.73557076923077,16.67114153846154,18.60671230769231,20.542283076923077,22.47785384615385,24.413424615384617,26.348995384615385,28.284566153846157,30.220136923076925,32.15570769230769,34.091278461538465,36.02684923076923,{"y":37.96242,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.8,14.735384615384616,16.67076923076923,18.60615384615385,20.54153846153846,22.47692307692308,24.412307692307692,26.34769230769231,28.283076923076926,30.21846153846154,32.15384615384616,34.08923076923077,36.02461538461539,{"y":37.96,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.8,14.73557076923077,16.67114153846154,18.60671230769231,20.542283076923077,22.47785384615385,24.413424615384617,26.348995384615385,28.284566153846157,30.220136923076925,32.15570769230769,34.091278461538465,36.02684923076923,{"y":37.96242,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.7,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.7,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.7,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.7,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.42,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.42,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.55,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.05,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.92,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":18.48,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16.62,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":13.35,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.8,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >